At Speratum, we're developing a robust RNAi platform targeting key oncogenic drivers in solid tumors.
Speratum Biopharma, Inc. has raised $581K in total funding. The most recent round was Convertible Note. The last funding was announced in November 2024.
Speratum Biopharma, Inc.'s investors include MassChallenge, Carao Ventures.
Speratum Biopharma, Inc. is headquartered in Houston, United States.
At Speratum, we're developing a robust RNAi platform targeting key oncogenic drivers in solid tumors.
Speratum Biopharma, Inc. is at the Convertible Note stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Speratum Biopharma, Inc. — Funding & Investors." VCBacked, November 5, 2024, https://www.vcbacked.co/company/speratum-biopharma-inc. Accessed August 13, 2026.
VCBacked. (2024). Speratum Biopharma, Inc. — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/speratum-biopharma-inc
{{cite web |title=Speratum Biopharma, Inc. — Funding & Investors |url=https://www.vcbacked.co/company/speratum-biopharma-inc |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated